CCCC · NASDAQ
C4 Therapeutics (CCCC) Stock Price & Fundamentals
C4 Therapeutics (CCCC) closed at $922.67 on Oct 9, 2026, down 0.11% from the previous close of $923.71.
Share price, past year
1Y +47.41%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $922.67 |
| Sep 30, 2026 | $914.27 |
| Aug 31, 2026 | $855.96 |
| Jul 31, 2026 | $817.88 |
| Jun 30, 2026 | $800.39 |
| May 29, 2026 | $794.97 |
| Apr 30, 2026 | $797.05 |
| Mar 31, 2026 | $762.40 |
| Feb 27, 2026 | $705.78 |
| Jan 30, 2026 | $650.88 |
| Dec 31, 2025 | $691.86 |
| Nov 28, 2025 | $675.99 |
| Oct 31, 2025 | $639.74 |
Key statistics
- Market cap
- $113.40B
- P/E (TTM)
- —
- EPS (TTM)
- −$0.91
- Revenue (TTM)
- $35.04M
- Net income (TTM)
- −$101.42M
- Shares outstanding
- 122.9M
- Dividend yield
- —
- 52-week range
- $611.08 – $923.71
C4 Therapeutics's market cap is $113.40B, based on a share price of $922.67 and 122.9M shares outstanding as of Jun 30, 2026.
Financials
C4 Therapeutics reported revenue of $35.95M for fiscal 2025, up 1.02% from fiscal 2024.
C4 Therapeutics reported a net loss of $104.99M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $35.95M | +1.0% | −$104.99M | −292.1% | −$1.27 | −$99.30M |
| FY2024ended Dec 31, 2024 | $35.58M | +71.4% | −$105.32M | −296.0% | −$1.52 | −$65.34M |
| FY2023ended Dec 31, 2023 | $20.76M | −33.3% | −$132.49M | −638.3% | −$2.67 | −$108.55M |
| FY2022ended Dec 31, 2022 | $31.10M | −32.1% | −$128.18M | −412.2% | −$2.62 | −$111.44M |
| FY2021ended Dec 31, 2021 | $45.79M | — | −$83.89M | −183.2% | −$1.82 | −$88.24M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $6.64M | −$23.64M | −$0.18 |
| Q1 FY2026ended Mar 31, 2026 | $6.15M | −$25.13M | −$0.20 |
| Q4 FY2025ended Dec 31, 2025 | $11.02M | −$20.49M | −$0.09 |
| Q3 FY2025ended Sep 30, 2025 | $11.23M | −$32.17M | −$0.44 |
| Q2 FY2025ended Jun 30, 2025 | $6.46M | −$26.02M | −$0.37 |
| Q1 FY2025ended Mar 31, 2025 | $7.24M | −$26.32M | −$0.37 |
| Q4 FY2024ended Dec 31, 2024 | $5.18M | −$34.57M | −$0.50 |
| Q3 FY2024ended Sep 30, 2024 | $15.36M | −$24.67M | −$0.35 |
Company profile
- Name
- C4 Therapeutics, Inc.
- Ticker
- CCCC
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Biological Products, (No Diagnostic Substances)
- Headquarters
- 490 Arsenal Way, Suite 120, Watertown, MA 02472
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001662579
Recent SEC filings
- Sep 25, 2026
- Aug 11, 2026
- Aug 11, 2026
- Jun 24, 2026
- Jun 11, 2026
- May 15, 2026
- May 12, 2026
- May 12, 2026
Frequently asked questions
What is C4 Therapeutics's stock price?
C4 Therapeutics (CCCC) closed at $922.67 on Oct 9, 2026, down 0.11% from the previous close of $923.71.
What is C4 Therapeutics's market cap?
C4 Therapeutics's market cap is $113.40B, based on a share price of $922.67 and 122.9M shares outstanding as of Jun 30, 2026.
How much revenue does C4 Therapeutics make?
C4 Therapeutics reported revenue of $35.95M for fiscal 2025, up 1.02% from fiscal 2024.
Does C4 Therapeutics pay a dividend?
C4 Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from C4 Therapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures